Literature DB >> 9670894

Vagus nerve stimulation.

S C Schachter1, C B Saper.   

Abstract

Left vagus nerve stimulation (VNS) is a promising new treatment for epilepsy. In 1997, VNS was approved in the United States as an adjunctive treatment for medically refractory partial-onset seizures in adults and adolescents. For some patients with partial-onset seizures, the adverse effects of antiepileptic drugs (AEDs) are intolerable; for others, no single AED or combination of anticonvulsant agents is effective. Cerebral resective surgery is an option to pharmacotherapy in some cases, but many patients with partial-onset seizures are not optimal candidates for intracranial surgery. VNS entails implantation of a programmable signal generator--the Neuro-cybernetic Prosthesis (NCP)--in the chest cavity. The stimulating electrodes of the NCP carry electrical signals from the generator to the left vagus nerve. Although the mechanism of action of VNS is not known, controlled studies have shown that it is safe and well-tolerated by patients with long-standing partial-onset epilepsy. Side effects, which are generally of mild to moderate severity, almost always disappear after the stimulation settings are adjusted. Encouraging results have also been reported in pediatric patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9670894     DOI: 10.1111/j.1528-1157.1998.tb01151.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  77 in total

1.  The management of epilepsy.

Authors:  D Smith; D Chadwick
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-06       Impact factor: 10.154

Review 2.  Neurostimulation therapy for epilepsy.

Authors:  Douglas Labar; Andy Dean
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

3.  Neural decoding of attentional selection in multi-speaker environments without access to clean sources.

Authors:  James O'Sullivan; Zhuo Chen; Jose Herrero; Guy M McKhann; Sameer A Sheth; Ashesh D Mehta; Nima Mesgarani
Journal:  J Neural Eng       Date:  2017-08-04       Impact factor: 5.379

4.  Primary Generalized Epilepsies.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-11       Impact factor: 3.598

Review 5.  Vagus nerve stimulation (VNS) for depression: what do we know now and what should be done next?

Authors:  Ziad Nahas; Carol Burns; Milton J Foust; Baron Short; Tal Herbsman; Mark S George
Journal:  Curr Psychiatry Rep       Date:  2006-12       Impact factor: 5.285

6.  Electrical stimulation of the vagus nerve enhances cognitive and motor recovery following moderate fluid percussion injury in the rat.

Authors:  Douglas C Smith; Arlene A Modglin; Rodney W Roosevelt; Steven L Neese; Robert A Jensen; Ronald A Browning; Richard W Clough
Journal:  J Neurotrauma       Date:  2005-12       Impact factor: 5.269

Review 7.  Therapeutic effects of vagus nerve stimulation in epilepsy and implications for sudden unexpected death in epilepsy.

Authors:  Steven C Schachter
Journal:  Clin Auton Res       Date:  2006-02       Impact factor: 4.435

Review 8.  Electrical stimulation of cranial nerves in cognition and disease.

Authors:  Devin Adair; Dennis Truong; Zeinab Esmaeilpour; Nigel Gebodh; Helen Borges; Libby Ho; J Douglas Bremner; Bashar W Badran; Vitaly Napadow; Vincent P Clark; Marom Bikson
Journal:  Brain Stimul       Date:  2020-02-23       Impact factor: 8.955

9.  The timing and amount of vagus nerve stimulation during rehabilitative training affect poststroke recovery of forelimb strength.

Authors:  Seth A Hays; Navid Khodaparast; Andrea Ruiz; Andrew M Sloan; Daniel R Hulsey; Robert L Rennaker; Michael P Kilgard
Journal:  Neuroreport       Date:  2014-06-18       Impact factor: 1.837

10.  Neural correlates of interoception: Effects of interoceptive focus and relationship to dimensional measures of body awareness.

Authors:  Emily R Stern; Stephanie J Grimaldi; Alexandra Muratore; James Murrough; Evan Leibu; Lazar Fleysher; Wayne K Goodman; Katherine E Burdick
Journal:  Hum Brain Mapp       Date:  2017-09-12       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.